OptiNose, Inc. Stock News

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in th...

YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.

OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Ear...

Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time

The stock market rally has been showing no sign of stopping, and while most of it has been driven by Big Tech, it is worth looking into some little-known penny stocks. These stocks usually see huge breakouts and trade at big premiums during bullish rallies.

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts' national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in...

OptiNose, Inc. (NASDAQ:OPTN ) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Schuyler van den Broek - Piper Sandler Glen Santangelo - Jefferies Matthew Caufield - H.C. Wainwright Operator Good day, and thank you for standin...

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.